Human amine transporter

Abstract

A Human amine transporter polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also provided are methods for detecting agonists and antagonists to such polypeptide and the use of agonists and antagonists for treating diseases related to the underexpression and over-expression of the Human amine transporter of the present invention. Also disclosed are methods for detecting mutations in the nucleic acid sequence encoding the polypeptide and for detecting altered levels of the soluble form of the polypeptide.

What is claimed is:  
     
         1 . An isolated polynucleotide selected from the group consisting of: 
 (a) a polynucleotide encoding a polypeptide having the deduced amino acid sequence of SEQ ID No. 2 and fragments, analogs or derivatives of said polypeptide; and    (b) a polynucleotide encoding a polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75980 and fragments, analogs or derivatives of said polypeptide.    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 2  wherein said polynucleotide encodes a polypeptide having the deduced amino acid sequence of SEQ ID No. 2.  
     
     
         4 . The polynucleotide of  claim 2  comprising the nucleotide sequence from nucleotide 1 to nucleotide 2885 of SEQ ID No. 1.  
     
     
         5 . A vector containing the DNA of  claim 2 .  
     
     
         6 . A host cell genetically engineered with the vector of  claim 5 .  
     
     
         7 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 6  the polypeptide encoded by said DNA.  
     
     
         8 . A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of  claim 5 .  
     
     
         9 . A polypeptide selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of SEQ ID No. 2 and fragments, analogs or derivatives thereof and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. 75980 and fragments, analog or derivatives of said polypeptide.  
     
     
         10 . An antibody against the polypeptide of  claim 9 .  
     
     
         11 . A compound effective as an agonist to the polypeptide of  claim 9 .  
     
     
         12 . A compound effective as an antagonist against the polypeptide of  claim 9 .  
     
     
         13 . A method for the treatment of a patient having need of human amine transporter activity comprising: administering to the patient a therapeutically effective amount of the compound of  claim 11 .  
     
     
         14 . A method for the treatment of a patient having need of human amine transporter activity comprising: administering to the patient a therapeutically effective amount of the polypeptide of  claim 9 , wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.  
     
     
         15 . A method for the treatment of a patient having need to inhibit human amine transporter activity comprising: administering to the patient a therapeutically effective amount of the compound of  claim 12 .  
     
     
         16 . A soluble fragment of the polypeptide of  claim 9  wherein the polypeptide binds a ligand for the receptor.  
     
     
         17 . A process for identifying compounds effective as antagonists or agonists to the a polypeptide of  claim 9  comprising: 
 expressing the polypeptide on the surface of a cell;  
 contacting the cell with a ligand known to be transported by the polypeptide and a compound to be screened;  
 determining the extent of ligand transported by the polypeptide; and  
 identifying if the compound to be screened is an agonist or antagonist.  
 
     
     
         18 . A process for determining whether a ligand not known to be capable of binding to the polypeptide of  claim 9  can bind thereto comprising: 
 contacting a mammalian cell which expresses the human amine transporter with a potential ligand;  
 detecting the presence of the ligand which binds to the transporter; and  
 determining whether the ligand binds to the transporter.  
 
     
     
         19 . A method for diagnosing a disease or a susceptibility to a disease related to under-expression of the polypeptide of  claim 9  comprising: 
 detecting mutations in the nucleic acid sequence encoding the polypeptide of  claim 14  in a sample derived from a host.  
 
     
     
         20 . A diagnostic process comprising: 
 analyzing for the presence of the polypeptide of claim  22  in a sample derived from a host.